Loading…
Lobbying Spend
—
Filings
52
Firms Hired
1
Active Period
2009–2021
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · second_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2010 · second_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · second_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $10,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · first_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2010 · first_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · first_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $40,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · fourth_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $20,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · third_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · third_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · third_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $10,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · second_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · second_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · second_quarter · Firm: BOSE PUBLIC AFFAIRS GROUP
Healthcare reform; Eshoo/Barton legislation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Client expense: — · Firm income: $10,000
Matched citations: S. 726
Source: Senate LDA